阿巴西普治疗活动性鸟枪弹样葡萄膜炎的疗效与安全性:一项前瞻性开放标签干预性概念验证试验
该前瞻性开放标签干预性概念验证试验纳入15例活动性鸟枪弹样葡萄膜炎(BU)患者,每周皮下注射阿巴西普125 mg/mL单药治疗。治疗1年时玻璃体混浊分级、中央脉络膜厚度(CCT)、荧光素血管造影(FA)评分、吲哚菁绿血管造影(ICGA)评分及双FA-ICGA总评分均显著改善,而最佳矫正视力(BCVA)和中央视网膜厚度(CRT)无显著变化,未报告严重不良事件。
要点
- 阿巴西普单药治疗活动性BU在1年时显著改善玻璃体混浊、CCT及FA/ICGA评分。
- BCVA和CRT在1年时无显著变化,不足以监测疾病活动。
- CCT是有前景的无创工具,双FA-ICGA评分有助于定量评估视网膜血管炎和脉络膜炎。
核心结论
- 阿巴西普对BU患者的视网膜血管炎和脉络膜炎均有很好疗效且耐受性良好。
- BCVA和CRT不足以监测疾病活动,CCT是检测早期活动性BU治疗反应的有前景无创工具,双FA-ICGA评分非常有助于定量评估视网膜血管炎和脉络膜炎。
研究设计与样本
- 前瞻性开放标签干预性概念验证试验,纳入15例活动性BU患者,每周皮下注射阿巴西普125 mg/mL单药治疗。
- 主要结局为治疗失败时间,次要目标为评估不同结局指标监测疾病活动的效用,安全性通过不良事件报告和系列血液分析评估。
主要发现
- 第1年终点时,玻璃体混浊分级显著改善(p=0.0014)。
- CCT显著改善(p=0.0011)。
- FA评分显著改善(p=0.0014),ICGA评分显著改善(p<0.001),双FA-ICGA总评分显著改善(p<0.001)。
- BCVA(p=0.8354)和CRT(p=0.3549)无显著变化。
- 未报告严重不良事件;15例中4例在第1年退出试验,其中2例治疗失败。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND/AIMS: Birdshot uveitis (BU) is a chronic autoimmune posterior uveitis, mostly affecting middle-aged Caucasians. There is a strong association with HLA-A29 and T-cell activation. Safety and efficacy of abatacept, an inhibitor of T-cell costimulation, is tested in active BU. METHODS: Fifteen patients with active BU were treated with monotherapy of weekly subcutaneous injections of abatacept 125 mg/mL. Time-to-treatment failure was evaluated as a primary outcome. The secondary objective was to evaluate the utility of different outcome measures to monitor disease activity. Safety was evaluated by adverse event reporting and serial blood analyses. RESULTS: At the year-1 endpoint, there was significant improvement in vitreous haze grade (p=0.0014), central choroidal thickness (CCT) (p=0.0011), Fluorescein Angiography (FA) Score (p=0.0014), Indocyanine Green Angiography (ICGA) Score (p<0.001) and total dual FA-ICGA Score (p<0.001). Best corrected visual acuity (BCVA) (p=0.8354) and central retinal thickness (CRT) (p=0.3549) did not change significantly. There were no serious adverse events reported. In total, 4 out of 15 patients left the trial during year 1 of whom 2 experienced treatment failure. CONCLUSIONS: Abatacept is very efficacious to treat both retinal vasculitis and choroiditis in patients with BU and is well tolerated. BCVA and CRT are inadequate to monitor disease activity. On the other hand, CCT is a promising non-invasive tool to detect treatment response in early active BU and dual FA-ICGA Score is very helpful to evaluate retinal vasculitis and choroiditis quantitatively. TRIAL REGISTRATION NUMBER: NCT03871361.
引用
- Schauwvlieghe PP, Van Calster J, Herbort CP, et al. Efficacy and safety of abatacept to treat active birdshot uveitis: a prospective open label interventional proof-of-concept trial. Br J Ophthalmol. 2024. PMID: 36585127. doi:10.1136/bjo-2022-321585
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。